A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of CNTO 1275, a Fully Human Anti-IL-12 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis
收藏DataCite Commons2025-01-02 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/00004695/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of this study is to evaluate the effectiveness and safety of CNTO 1275 (ustekinumab) in patients with psoriatic arthritis.
提供机构：
Vivli
创建时间：
2019-09-19
